| Autor: |
Ceccarelli, Claudio, Santini, Donatella, Gamberini, Michela, Taffurelli, Mario, Chieco, Pasquale, Piana, Simonetta, Pileri, Stefano, Marrano, Domenico |
| Zdroj: |
Breast Cancer Research & Treatment; Nov1999, Vol. 58 Issue 2, p107-114, 8p |
| Abstrakt: |
We tested three ErbB 2 monoclonal antibodies (MoAbs) specific to the intracytoplasmic internal domain (clone CB 11) and the extracellular glycosylated peptide domain (clones CBE1 and Tab250) in 351 primary invasive breast carcinomas. ErbB 2 immunodetection allowed us to differentiate three main groups: group 1 (62.7%) lacked both MoAb ErbB 2 domains (erb −/−); group 2 stained for both domains (erb +/+) (26.5%); group 3 stained for the internal domain only (erb +/−) (10.8%). The relationships among these groups and nodal status (N) were statistically significant, with N+ cases reaching the highest value (89.2%) in the erb +/− group. Lack of immunostaining in the external domain thus seems to be associated with increased metastatic spread. At variance analysis the difference in hormonal receptor content between groups 1 and 3 was not significant; while between groups 1 and 2 it was. The growth fraction of groups 2 and 3 was significantly higher than that of group 1. Our results showed that anti-ErbB-2 MoAb clone CB 11 was able to detect a higher number of ErbB-2 expressing cases than the two that are specific for the external domain (clones Tab 250 and CBE1). Due to the strong association between group 3 cases and the highest metastatic potential, this aggressive group could be identified only with the use of an internal-domain specific MoAb CB11, which thus seems to present a better discriminative power as a diagnostic marker in the biopathological characterization of breast carcinoma. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink